teva pharmaceuticals introduces the first generic glp-1 for weight loss Announces Launch of of Victoza (liraglutide) in United States. #glp1 #obesitymedicine #diabetes #saxenda Teva wins US obesity approval

"There is no one treatment that works for everyone." Why are these pages a bad thing

Huang, G., Zhang, Y., Zhang, Y

Martin, R

Weeks 1 through 12 showed moderate but accelerating weight loss as titration progressed

Obesity: a much higher study focus than other metabolic disease areas Precisely classifying the clinical trial types in the metabolic domain can be a fraught affair given the variability of descriptions, but taking a conservative approach to classification clearly reveals that trials involving obesity and overweight outnumber those focused more on type 2 diabetes about four to one

The National Eating Disorders Association has similarly noted that the few studies conducted to date have involved small sample sizes and short follow-up windows of three to six months, leaving long-term outcomes almost entirely unknown